NCT07279714已完成2 期
Fisetin Intervention Study in Mild Alzheimer's Disease
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 5
- 试验地点
- 2
- 主要终点
- Incidence of Treatment-Emergent Adverse Events (Safety and tolerability of fisetin)
研究概览
简要总结
This pilot study will evaluate the safety and tolerability of the natural health product, fisetin, in older adults with mild cognitive impairment or mild Alzheimer's disease dementia.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 60 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Mild cognitive impairment due to Alzheimer's disease OR mild Alzheimer Dementia
- •Moca score of 11 or higher
- •Stable psychotropics and cognitive enhancing medications
排除标准
- •Known hypersensitivity or allergy to fisetin
- •Presence of any medical condition, or abnormal routine blood test, that the investigator believes would put the subject at risk or would preclude the patient from completing all aspects of the trial
- •Unstable medical disorders
- •Ongoing treatment for active infection with antibiotics/antifungals
- •Ongoing treatment for cancer
- •Active alcohol or substance use disorder
- •Recent active bleeding
- •Patients taking oral anticoagulants, anti-cancer, anti-seizure medications, or other medications that could have a significant interaction with fisetin
- •Use within the last month of other senolytic supplements, antioxidant supplements, natural health products
- •Other neurologic or neurodegenerative conditions impacting cognition
- •Active Major Depressive Episode, active suicidal thoughts or psychosis
- •Any thing that would preclude the ability to undergo an MRI scan
研究组 & 干预措施
Fisetin
Experimental
干预措施: Fisetin (Other)
结局指标
主要结局
Incidence of Treatment-Emergent Adverse Events (Safety and tolerability of fisetin)
时间窗: 30 days
Measured using AE reports
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
进行中（未招募）
1 期
AK152 注射液在健康受试者和阿尔茨海默病受试者中的 I 期临床试验CTR20254703108
进行中（未招募）
2 期
在中重度特应性皮炎患者中评价试验性化合物的疗效和安全性的平台研究CTR2025328714
进行中（未招募）
2 期
在中重度特应性皮炎患者中评价试验性化合物的疗效和安全性的平台研究CTR2025328714
已完成
2 期
Trial of Rifaximin in Probable Alzheimer's DiseaseAlzheimer's DiseaseNCT03856359Duke University10
已完成
4 期
Magnetic Resonance Spectroscopy Study of Memantine in Alzheimer's DiseaseAlzheimer DiseaseNCT00551161Northwell Health12